Antifungal drugs: Predicting clinical efficacy with pharmacodynamics

Expert Review of Clinical Pharmacology

Volumn 2, Issue 4, 2009, Pages 373-379

  Nailor, Michael D ^a,b   Chandrasekar, Pranatharthi H ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungals; Efficacy; Pharmacodynamics

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LIPOSOME; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

AREA UNDER THE CURVE; BONE MARROW TOXICITY; CANDIDIASIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; HUMAN; HYPOKALEMIA; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PREDICTION; REVIEW; SIDE EFFECT;

EID: 70149093202     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.14     Document Type: Review

References (53)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29, 239-244 (1999).
2. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3, 685-702 (2003).
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP; National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35, 627-630 (2002).
4. Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients; emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. 37, 221-229 (2003).
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917 (2002).
6. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 20, 679-697 (2006).
7. Ernst EJ, Roling EE, Petzold CR et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46, 3846-3853 (2002).
8. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41, 2326-2332 (1997).
9. Louie A, Deziel M, Liu W et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49, 5058-5068 (2005).
10. Andes D, Marchillo K, Lowther J et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47, 1187-1192 (2003).
11. Buell D, Kovand L, Drake T et al. Alternate day dosing of micafungin in treatment of esophageal candidiasis. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 27-30 September 2006 (Abstract M719).
12. Pappas PG, Rotstein CM, Betts RF et al. Micafungin vs caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45, 883-893 (2007).
13. Betts R, Nucci M, Talwar D et al. A multicenter, double-blind trial of a higher caspofungin dose versus standard caspofungin dose in the treatment of invasive candidiasis. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society if America 46th Annual Meeting, Washington, DC, USA, 25-28 October 2008 (Abstract M1847).
14. Louie A, Drusano GL, Banerjee P et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42, 1105-1109 (1998).
15. Andes D, Van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43, 2116-2120 (1999).
16. Andes D, Marchillo K, Stamstad T et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47, 3165-3169 (2003).
17. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48, 137-142 (2004).
18. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro - in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24, 235-247 (1997).
19. Lee SC, Fung CP, Huang JS et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob. Agents Chemother. 44, 2715-2718 (2000).
20. Clancy CJ, Yu VL, Morris AJ et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49, 3171-3177 (2005).
21. Fan-Havard P, Papano D, Smith SM et al. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35, 2302-2305 (1991).
22. Walmsley S, King S, McGeer A et al. Oropharyngeal candidiasis in patients with human immunodefiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin. Infect. Dis. 32, 1554-1561 (2001).
23. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42, 1179-1186 (2006).
24. Koks CHW, Meenhorst PL, Bult A et al. Itraconazole solution: summary of pharmacokinetic reatures and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected patients. Pharmacol. Res. 46, 195-201 (2002).
25. Glasmacher A, Hahn C, Leuner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42, 443-451 (1999).
26. Courtney R, Pai S, Laughlin M et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47, 2788-2795 (2003).
27. Ezzet F, Wexler D, Courtney R et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44, 211-220 (2005).
28. Courtney R, Wexler D, Radwanski E et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57, 218-222 (2004).
29. Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant receipients. Antimicrob. Agents Chemother. 50, 1993-1999 (2006).
30. Krishna G, Martinho MS, Chandrasekar P et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27, 1627-1636 (2007).
31. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 39, 842-849 (2004).
32. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46, 2546-2553 (2002).
33. Ikeda Y, Umemura K, Kondo D et al. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Infect. Dis. 75, 586-587 (2004).
34. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-637 (2003).
35. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic dtug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin: Infect. Dis. 46, 201-211 (2008).
36. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50, 1570-1572 (2006).
37. Segal BH. Aspergillosis. N. Engl. J. Med. 360, 1870-1884 (2009).
38. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 327-360 (2008).
39. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agens against Candida, albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44, 1108-1111 (2000).
40. Turnidge JD, Gudmundsson S, Vogelman B et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34, 83-92 (1994).
41. Andes D, Stamstad T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidasis model. Antimicrob. Agents Chemother. 45, 922-926 (2001).
42. Andes D, Safdar N, Marchillo K et al. Pharmacokinetic - pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50, 674-684 (2006).
43. Wiederhold NP, Tam VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50, 469-473 (2006).
44. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 20, 679-697 (2006).
45. Park BJ, Arthington-Skaggs BA, Hajjeh RA et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50, 1287-1292 (2006).
46. Bicanic T, Wood R, Meintjes G et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin. Infect. Dis. 47, 123-130 (2008).
47. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmbiLoad trial). Clin. Infect. Dis. 44, 1289-1297 (2007).
48. Andes D, Van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidasis model. Antimicrob. Agents Chemother. 44, 938-942 (2000).
49. Karyotakis NC, Anaissie EJ. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidasis. Antimicrob. Agents Chemother. 40, 2907-2908 (1996).
50. Hope WW, Warn PS, Sharp A et al. Surface response modeling to examine the combination of amphotericin B deoycholate and 5-fluorocytosine for treatment of invasive candidiasis. J. Infect. Dis. 192, 673-680 (2005).
51. Te Dorsthorst DT, Verweij PE, Meis JF et al. In vitro interactions between amphotericin B, itraconazole and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob. Agents Chemother. 48, 2007-2013 (2004)
52. Te Dorsthorst DT, Verweij PE, Meis JF et al. Efficacy and pharmadynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 49, 4220-4226 (2005).
53. Karyotakis NC, Anaissie EJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect Dis. 15, 1003-1018 (1992).